Detalles de la búsqueda
1.
International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia.
Blood
; 132(3): 264-276, 2018 07 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-29720486
2.
Automated Flow Cytometric MRD Assessment in Childhood Acute B- Lymphoblastic Leukemia Using Supervised Machine Learning.
Cytometry A
; 95(9): 966-975, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31282025
3.
Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
Pediatr Blood Cancer
; 66(5): e27590, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30561169
4.
Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trial.
Br J Haematol
; 183(1): 96-103, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30028023
5.
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Blood
; 127(17): 2101-12, 2016 04 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-26888258
6.
Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma.
Haematologica
; 102(12): 2086-2096, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28983060
7.
Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
Haematologica
; 100(7): 935-44, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26001791
8.
High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Haematologica
; 99(1): 103-10, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23911702
9.
Peripheral blood sCD3⻠CD4⺠T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma.
Hematol Oncol
; 32(1): 16-21, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23798351
10.
High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
Blood
; 118(13): 3504-11, 2011 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-21715318
11.
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.
Blood
; 118(8): 2077-84, 2011 Aug 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-21719599
12.
IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Haematologica
; 98(3): 428-32, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22875627
13.
CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia.
Blood
; 115(18): 3763-71, 2010 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-20228269
14.
Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome.
Haematologica
; 97(3): 402-9, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22058224
15.
Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.
Haematologica
; 97(10): 1582-93, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22581001
16.
NOTCH1 mutation, TP53 alteration and myeloid antigen expression predict outcome heterogeneity in children with first relapse of T-cell acute lymphoblastic leukemia.
Haematologica
; 102(7): e249-e252, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28360149
17.
Automated identification of cell populations in flow cytometry data with transformers.
Comput Biol Med
; 144: 105314, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35247762
18.
An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report.
Cancers (Basel)
; 13(23)2021 Dec 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34885257
19.
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.
Blood
; 112(10): 3982-8, 2008 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18780832
20.
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.
Blood
; 111(9): 4477-89, 2008 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18285545